IRMD insider sales disclosed under Rule 10b5-1 trading plan

Rhea-AI Filing Summary

IRADIMED Corp (IRMD) CEO, President, Chairman and Director Roger E. Susi reported open-market sales of common stock on November 3, 2025.

The filing lists six tranches by an indirect holder, the Phillip Susi 2008 Dynasty Trust, including 1,618 shares at a weighted average price of $83.85, 1,335 shares at $83.22, 900 shares at $81.71, 601 shares at $81.28, 446 shares at $79.82, and 100 shares at $84.60. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.

Following the reported transactions, the filing shows 2,322,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, and 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of certain securities except to the extent of pecuniary interest.

Insights

Corporate governance and insider transactions analyst

Routine Form 4 disclosing planned insider sales under Rule 10b5-1.

The report details multiple open-market sales on November 3, 2025 by an indirect holder associated with Roger E. Susi. Each tranche notes a weighted average price, with execution ranges disclosed in footnotes, aligning with standard Section 16 reporting practices.

The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025, which pre-establishes trading parameters. The filing lists indirect holdings across named trusts and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.

As a Form 4, this is informational; actual impact depends on holder decisions and market context. Subsequent filings may provide additional transaction details as trades occur under the plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2025		S(1)		446	D	$79.82(2)	2,327,054	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	11/03/2025		S(1)		601	D	$81.28(3)	2,326,453	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	11/03/2025		S(1)		900	D	$81.71(4)	2,325,553	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	11/03/2025		S(1)		1,335	D	$83.22(5)	2,324,218	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	11/03/2025		S(1)		1,618	D	$83.85(6)	2,322,600	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	11/03/2025		S(1)		100	D	$84.6	2,322,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(7)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $79.50 to $80.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $80.61 to $81.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $81.50 to $81.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $82.58 to $83.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $83.52 to $84.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IRMD disclose in this Form 4?

Open-market sales of common stock on November 3, 2025 by an indirect holder associated with CEO Roger E. Susi, reported in six tranches with weighted average prices.

Were the IRMD insider sales under a Rule 10b5-1 plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.

What prices were reported for the IRMD insider sales?

Weighted average prices reported include $79.82, $81.28, $81.71, $83.22, $83.85, and $84.60.

How many IRMD shares were shown as indirectly held after the transactions?

The filing shows 2,322,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 by the Roger E. Susi Revocable Trust, and 2,062,500 by the Matthew Susi 2008 Dynasty Trust.

What is Roger E. Susi’s relationship to IRMD?

He is listed as CEO, President, Chairman, Director, and a 10% Owner.

Do the footnotes disclose trading ranges for each tranche?

Yes. Each tranche includes a price range, and the weighted average price is reported with an undertaking to provide full trade details upon request.